China
Africa
Explore chapters and articles related to this topic
Stimulants and psychedelics
Published in Ilana B. Crome, Richard Williams, Roger Bloor, Xenofon Sgouros, Substance Misuse and Young People, 2019
ICD-10 has a separate category for mental and behavioural disorders due to use of cocaine; however, diagnostic criteria for acute intoxication due to use of cocaine and a cocaine withdrawal state are virtually identical with the corresponding categories of other stimulants (including caffeine) (WHO, 1993). DMS-5 does include cocaine-related disorders in the stimulant category (American Psychiatric Association and American Psychiatric Association, DSM-5 Task Force, 2013).
Comorbidities among persons living with HIV (PLWH) in Florida: a network analysis
Published in AIDS Care, 2023
Shyfuddin Ahmed, Angel B. Algarin, Hsu Thadar, Zhi Zhou, Tanjila Taskin, Krishna Vaddiparti, Karina Villalba, Yan Wang, Nicole Ennis, Jamie P. Morano, Charurut Somboonwit, Robert L Cook, Gladys E. Ibañez
In terms of the specific diagnosis of the comorbidities, hypertensive disorders (I10–I16: 35.8%) were the predominant cause of comorbidities followed by dyslipidemia (E78: 25.7%) (Table 3). Viral hepatitis was the major infectious disease (B15–B19: 17.1%) followed by all stages of syphilis (A51–A53:12.0%) and other sexually transmitted infections (STIs) (A54–A59, A63–64) at 8.7% that include gonococcal, chlamydial, and/or trichomonas infection. Any site herpes simplex virus (A60, B00) was prevalent among 7.8% of the PLWH. About 23.9% of the PLWH had major depressive disorder (F32–F33), 8.1% had anxiety disorder (A41) and 7.9% had bipolar disorder (F31). Nicotine dependence (F17: 12.8%), alcohol (F10: 5.4%) and cocaine-related disorders (F14: 5.8%) were the major psychoactive substance use disorders among our sample. About 3.0% of the PLWH had cannabis-related (F12) and 3.4% had inhalant-related (F18) disorders. Diabetes mellitus (E08–E13), chronic respiratory disease including chronic obstructive pulmonary disease (J45), and asthma (J44) were prevalent at 11.8%, 5.4%, and 7.9% of PLWH respectively.
Cervical cancer screening, abnormal results, and follow-up in women with substance use-related diagnoses
Published in Substance Abuse, 2022
McKenna C. Eastment, Ayushi Gupta, Jocelyn James, Barbra A. Richardson, Leeya Pinder, H. Nina Kim, Anna Wald, Judith I. Tsui
The primary exposure was having at least one or more substance use-related diagnosis. Women were assigned an exposure status if they met criteria to be included in the study population. Substance use-related diagnoses were defined using only International Classification of Diseases, 10th Edition (ICD10) codes for opioid-related disorders, cocaine-related disorders, other stimulant-related disorders, other psychoactive substance abuse, inhalant use/abuse, sedative/hypnotic/anxiolytic abuse, hallucinogen abuse, cannabis use, and alcohol abuse/misuse (Supplementary Appendix 2), similar to other studies.25–27 Nicotine-related disorders were not included in the exposed category for the primary analysis. Codes related to remission or cessation of substance use were not used as this analysis focused on active use. Overdose and toxic ingestion were also not included in these analyses because of a lack of detail for the specific substance used and intent of use in many of these ICD10 codes. The primary outcomes were receipt of cervical cancer screening identified through cytology reports (from Papanicolaou smears) and HPV test results, an abnormal cervical cancer screening result, and in cases of abnormal screening results, follow-up testing or procedures. An abnormal cervical cancer screening result was defined using cytology reports characterized using the Bethesda Criteria: high-risk HPV positive (types 16, 18, 31, 33, 35, 39, 45, 51, 56, 58, 59, 69), atypical squamous cells of undetermined significance (ASC-US), atypical squamous cells, cannot exclude HSIL (ASC-H), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL) and squamous cell carcinoma. Follow-up was defined as any second Papanicolaou (pap) smear result, any second HPV result, or a procedure code indicating colposcopy, Loop Electrosurgical Excision Procedure (LEEP), cryotherapy, biopsy, ablation, or surgical removal (Supplementary Appendix 3) within the study period.